LGT Capital Partners LTD. Buys 190,950 Shares of Teleflex Incorporated (NYSE:TFX)

LGT Capital Partners LTD. increased its position in shares of Teleflex Incorporated (NYSE:TFX - Free Report) by 285.4% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 257,864 shares of the medical technology company's stock after buying an additional 190,950 shares during the quarter. Teleflex accounts for 1.9% of LGT Capital Partners LTD.'s portfolio, making the stock its 18th biggest holding. LGT Capital Partners LTD. owned approximately 0.55% of Teleflex worth $64,296,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors have also added to or reduced their stakes in the company. Commonwealth Equity Services LLC boosted its holdings in Teleflex by 0.9% during the first quarter. Commonwealth Equity Services LLC now owns 4,688 shares of the medical technology company's stock valued at $1,187,000 after purchasing an additional 42 shares in the last quarter. Mercer Global Advisors Inc. ADV boosted its holdings in Teleflex by 3.5% during the third quarter. Mercer Global Advisors Inc. ADV now owns 1,411 shares of the medical technology company's stock valued at $284,000 after purchasing an additional 48 shares in the last quarter. First Horizon Advisors Inc. boosted its holdings in Teleflex by 39.1% during the first quarter. First Horizon Advisors Inc. now owns 178 shares of the medical technology company's stock valued at $45,000 after purchasing an additional 50 shares in the last quarter. Huntington National Bank raised its stake in shares of Teleflex by 26.5% in the third quarter. Huntington National Bank now owns 253 shares of the medical technology company's stock valued at $50,000 after acquiring an additional 53 shares during the last quarter. Finally, Cambridge Investment Research Advisors Inc. raised its stake in shares of Teleflex by 2.5% in the first quarter. Cambridge Investment Research Advisors Inc. now owns 2,231 shares of the medical technology company's stock valued at $792,000 after acquiring an additional 54 shares during the last quarter. 95.62% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of research analysts have recently issued reports on TFX shares. Royal Bank of Canada cut their target price on shares of Teleflex from $272.00 to $265.00 and set an "outperform" rating for the company in a research note on Friday, February 23rd. Morgan Stanley upgraded shares of Teleflex from an "equal weight" rating to an "overweight" rating and set a $261.00 target price for the company in a research note on Monday, December 4th. JMP Securities restated a "market outperform" rating and issued a $285.00 price objective on shares of Teleflex in a research report on Friday, February 23rd. Raymond James boosted their price objective on shares of Teleflex from $227.00 to $271.00 and gave the stock an "outperform" rating in a research report on Wednesday, December 20th. Finally, StockNews.com cut shares of Teleflex from a "buy" rating to a "hold" rating in a research report on Friday, February 23rd. Five research analysts have rated the stock with a hold rating and six have given a buy rating to the company's stock. Based on data from MarketBeat, Teleflex presently has an average rating of "Moderate Buy" and an average target price of $265.56.

Teleflex Trading Up 1.0 %

Shares of Teleflex stock traded up $2.30 on Friday, hitting $226.17. 288,953 shares of the company's stock traded hands, compared to its average volume of 285,313. Teleflex Incorporated has a one year low of $177.63 and a one year high of $276.43. The stock has a market capitalization of $10.64 billion, a PE ratio of 30.04, a price-to-earnings-growth ratio of 2.14 and a beta of 1.11. The company has a debt-to-equity ratio of 0.39, a current ratio of 2.32 and a quick ratio of 1.29. The firm's 50-day moving average price is $235.35 and its two-hundred day moving average price is $224.20.

Teleflex (NYSE:TFX - Get Free Report) last announced its quarterly earnings results on Thursday, February 22nd. The medical technology company reported $3.38 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.26 by $0.12. Teleflex had a net margin of 11.98% and a return on equity of 14.98%. The company had revenue of $773.90 million during the quarter, compared to analyst estimates of $769.01 million. During the same quarter in the previous year, the business earned $3.52 EPS. The firm's revenue was up 2.1% on a year-over-year basis. On average, research analysts expect that Teleflex Incorporated will post 13.73 EPS for the current fiscal year.

Teleflex Announces Dividend

The company also recently declared a quarterly dividend, which was paid on Friday, March 15th. Stockholders of record on Friday, March 1st were issued a $0.34 dividend. This represents a $1.36 annualized dividend and a dividend yield of 0.60%. The ex-dividend date of this dividend was Thursday, February 29th. Teleflex's dividend payout ratio (DPR) is 18.06%.

Insider Activity

In related news, VP Cameron P. Hicks sold 7,401 shares of the company's stock in a transaction on Tuesday, March 5th. The shares were sold at an average price of $225.00, for a total value of $1,665,225.00. Following the completion of the transaction, the vice president now directly owns 10,050 shares of the company's stock, valued at approximately $2,261,250. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. 1.41% of the stock is owned by company insiders.

About Teleflex

Teleflex Incorporated designs, develops, manufactures, and supplies single-use medical devices for common diagnostic and therapeutic procedures in critical care and surgical applications worldwide. The company provides vascular access products that comprise Arrow branded catheters, catheter navigation and tip positioning systems, and intraosseous access systems for the administration of intravenous therapies, the measurement of blood pressure, and the withdrawal of blood samples through a single puncture site.